Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2020-07-16 Sale |
2020-07-17 6:02 pm |
Stoke Therapeutics Inc. | STOK | Nash Huw M. COO & CBO |
1,900 | $25.06 | $47,614 | 223,011 (Direct) |
View |
| 2020-07-07 Sale |
2020-07-09 5:43 pm |
Stoke Therapeutics Inc. | STOK | Walker Robin A. Chief Legal Officer, CCO & Sec |
941 | $22.5 | $21,173 | 0 (Direct) |
View |
| 2020-07-07 Sale |
2020-07-09 5:41 pm |
Stoke Therapeutics Inc. | STOK | Nash Huw M. COO & CBO |
913 | $22.41 | $20,457 | 0 (Direct) |
View |
| 2020-07-01 Sale |
2020-07-02 6:08 pm |
Stoke Therapeutics Inc. | STOK | Nash Huw M. COO & CBO |
3,800 | $23.15 | $87,968 | 224,911 (Direct) |
View |
| 2020-06-01 Sale |
2020-06-03 4:58 pm |
Stoke Therapeutics Inc. | STOK | Ticho Barry Chief Medical Officer |
1,365 | $27.39 | $37,387 | 344,373 (Direct) |
View |
| 2020-06-01 Sale |
2020-06-03 4:57 pm |
Stoke Therapeutics Inc. | STOK | Liau Gene EVP Research & Preclinical Dev |
20,000 | $26.35 | $527,037 | 85,389 (Direct) |
View |
| 2020-06-01 Sale |
2020-06-03 4:55 pm |
Stoke Therapeutics Inc. | STOK | Nash Huw M. COO & CBO |
2,107 | $27.18 | $57,263 | 228,711 (Direct) |
View |
| 2020-05-22 Sale |
2020-05-26 5:58 pm |
Stoke Therapeutics Inc. | STOK | Liau Gene EVP Research & Preclinical Dev |
7,500 | $30 | $225,000 | 147,566 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2020-07-16 Exercise |
2020-07-17 6:02 pm |
N/A N/A |
Stoke Therapeutics Inc. | STOK | Nash Huw M. COO & CBO |
1,900 | $2.19 | 223,011 (Direct) |
View |
| 2020-07-16 Exercise |
2020-07-17 6:02 pm |
N/A 2018-12-12 |
Stoke Therapeutics Inc. | STOK | Nash Huw M. COO & CBO |
1,900 | $0 | 223,011 (Direct) |
View |
| 2020-07-01 Exercise |
2020-07-02 6:08 pm |
N/A N/A |
Stoke Therapeutics Inc. | STOK | Nash Huw M. COO & CBO |
3,800 | $2.19 | 224,911 (Direct) |
View |
| 2020-07-01 Exercise |
2020-07-02 6:08 pm |
N/A 2018-12-12 |
Stoke Therapeutics Inc. | STOK | Nash Huw M. COO & CBO |
3,800 | $0 | 224,911 (Direct) |
View |
| 2020-06-03 Option Award |
2020-06-05 5:32 pm |
N/A 2030-06-02 |
Stoke Therapeutics Inc. | STOK | TZIANABOS ARTHUR Director |
14,777 | $0 | 14,777 (Direct) |
View |
| 2020-06-03 Option Award |
2020-06-05 5:31 pm |
N/A 2020-06-02 |
Stoke Therapeutics Inc. | STOK | Smith Julie Director |
29,555 | $0 | 29,555 (Direct) |
View |
| 2020-06-03 Option Award |
2020-06-05 5:29 pm |
N/A 2030-06-02 |
Stoke Therapeutics Inc. | STOK | LEVIN ARTHUR A Director |
14,777 | $0 | 14,777 (Direct) |
View |
| 2020-06-03 Option Award |
2020-06-05 5:27 pm |
N/A 2030-06-02 |
Stoke Therapeutics Inc. | STOK | Krainer Adrian R. Director |
14,777 | $0 | 14,777 (Direct) |
View |
| 2020-06-03 Option Award |
2020-06-05 5:26 pm |
N/A 2030-06-02 |
Stoke Therapeutics Inc. | STOK | Harrison Seth Loring Director 10% Owner |
14,777 | $0 | 14,777 (Direct) |
View |
| 2020-06-03 Option Award |
2020-06-05 5:12 pm |
N/A 2030-06-02 |
Stoke Therapeutics Inc. | STOK | Burstein Jennifer Director |
14,777 | $0 | 14,777 (Direct) |
View |
Ownership |
2020-06-05 5:10 pm |
N/A N/A |
Stoke Therapeutics Inc. | STOK | Smith Julie Director |
0 | $0 | 0 (Direct) |
View |
| 2020-06-01 Exercise |
2020-06-03 4:58 pm |
N/A N/A |
Stoke Therapeutics Inc. | STOK | Ticho Barry Chief Medical Officer |
131,147 | $0.6 | 344,373 (Direct) |
View |
| 2020-06-01 Exercise |
2020-06-03 4:58 pm |
N/A N/A |
Stoke Therapeutics Inc. | STOK | Ticho Barry Chief Medical Officer |
42,880 | $2.19 | 344,373 (Direct) |
View |
| 2020-06-01 Exercise |
2020-06-03 4:58 pm |
N/A 2028-04-02 |
Stoke Therapeutics Inc. | STOK | Ticho Barry Chief Medical Officer |
174,027 | $0 | 344,373 (Direct) |
View |
| 2020-06-01 Exercise |
2020-06-03 4:57 pm |
N/A N/A |
Stoke Therapeutics Inc. | STOK | Liau Gene EVP Research & Preclinical Dev |
20,000 | $2.19 | 85,389 (Direct) |
View |
| 2020-06-01 Exercise |
2020-06-03 4:57 pm |
N/A 2028-12-12 |
Stoke Therapeutics Inc. | STOK | Liau Gene EVP Research & Preclinical Dev |
20,000 | $0 | 85,389 (Direct) |
View |
| 2020-06-01 Exercise |
2020-06-03 4:55 pm |
N/A N/A |
Stoke Therapeutics Inc. | STOK | Nash Huw M. COO & CBO |
2,107 | $2.19 | 228,711 (Direct) |
View |
| 2020-06-01 Exercise |
2020-06-03 4:55 pm |
N/A 2018-12-12 |
Stoke Therapeutics Inc. | STOK | Nash Huw M. COO & CBO |
2,107 | $0 | 228,711 (Direct) |
View |
| 2020-05-22 Exercise |
2020-05-26 5:58 pm |
N/A N/A |
Stoke Therapeutics Inc. | STOK | Liau Gene EVP Research & Preclinical Dev |
7,500 | $0.6 | 147,566 (Direct) |
View |
| 2020-05-22 Exercise |
2020-05-26 5:58 pm |
N/A 2028-04-02 |
Stoke Therapeutics Inc. | STOK | Liau Gene EVP Research & Preclinical Dev |
7,500 | $0 | 147,566 (Direct) |
View |